Educational Point / Counter Point: Educational Point/ Counter Point: Has Photon RT Hit the Limits?

Bulent Aydogan, PhD
Associate Professor and Director of Medical Physics at UIC
University of Chicago



Speakers

Stephen Hahn, MD

Professor and Chair of Radiation Oncology, UT MD Anderson Cancer Center


Harald Paganetti, PhD


Professor and Director of Research, MGH


Cedric Yu, PhD

Professor of Radiation Oncology, University of Maryland President and CEO, Xcision Medical Systems, LLC











Do we need much higher dose conformality than photon can provide?

- A. Yes
- B. No



Organ motion West Notice Courtesy of S. Mutic

Considering the fact that there are considerable uncertainties in RT from target definition to set up to organ motion to the extent of micro disease, do we want higher dose conformality than photon RT can provide?

A. Yes

B. No

Does proton beam produce superior dose distributions over IMRT for prostate cancer?

- A. Yes
- B. No



Rep Pract Oncol Radiother. 2013 Nov; 18(6): 338–342.

Published online 2013 Jul 3. doi: 10.1016/j.rpor.2013.06.001

Proton beam and prostate cancer: An evolving debate

Anthony Zietman*

The work of the Massachusetts General Hospital has tested a number of hypotheses:



Does proton beam produce superior dose distributions over IMRT for prostate cancer?

The answer is mixed. There is undoubtedly less of a "dose bath" to the anterior and posterior tissues but more radiation passes through the femoral heads and, because of beam uncertainty, the high-dose volume is actually a little larger with protons than IMRT.



Critical Organ Dose

- Two regions associated with morbidities (the prostatic urethra and peri-prostatic nerve bundles) are treated equally with the two techniques.
- The volume of rectum treated likely depends more on image guidance, choice of margins, and the use or not of a rectal balloon than it does the delivery technique.


Can photon RT continue to improve in order to provide the dose conformality needed to further cancer care?

A. Yes

B. No



Improvement in photon RT →



Do we need clinical trial evidence beyond planning comparison evidence of improved dosimetry to justify Proton RT?

A) Yes

B) No




The main reason we use proton to treat prostate cancer is the need for higher doses (more conformal) for better outcome

1. Yes

2. No





Do we have enough scientific and clinical evidence to treat with protons? A) Yes B) No

Proton RT will be the eventual future standard for the radiation treatment of prostate.

- A) Yes
- B) No
- C) I am not sure



If you answered "NO" to the previous						
question. Which one of the followings						
had influenced your answer the						
most?						

- A) Economics
- B) Lack of clinical evidence
- C) Organ motion
- D) Technology has not matured yet

